Drug Information

Drug (ID: DG01793) and It's Reported Resistant Information

• Name: Kainic acid
• Synonyms: Kainic acid; 487-79-6; Digenin; Digenic acid; Helminal; Kainate; L-alpha-Kainic acid; alpha-Kainic acid; Digensaeure; Kainsaeure; Acidum kainicum; Acide kainique; Acido kainico; C10H15NO4; 3-Pyrrolidineacetic acid, 2-carboxy-4-(1-methylethenyl)-, (2S,3S,4S)-; UNII-SIV03811UC; alpha- Kainic acid; rac Kainic Acid; CHEMBL275040; SIV03811UC; CHEBI:31746; 3-Pyrrolidineacetic acid, 2-carboxy-4-isopropenyl-; (2S,3S,4S)-3-(Carboxymethyl)-4-(prop-1-en-2-yl)pyrrolidine-2-carboxylic acid; NSC136038; 3-(Carboxymethyl)-4-isopropenylproline; (3S,4S)-3-(carboxymethyl)-4-prop-1-en-2-yl-L-proline; NCGC00024504-05; (3S,4R)-3-(carboxymethyl)-4-(prop-1-en-2-yl)-L-proline; NSC 136038; (2S-(2alpha,3beta,4beta))-2-carboxy-4-(1-methylethenyl)-3-pyrrolidineacetic acid; DSSTox_CID_20526; DSSTox_RID_79503; DSSTox_GSID_40526; (2S,3S,4S)-Carboxy-4-(1-methylethenyl)-3-pyrrolidineacetic acid; Kainic acid [INN:JAN]; CAS-487-79-6; Acide kainique [INN-French]; Acido kainico [INN-Spanish]; Acidum kainicum [INN-Latin]; 2-Carboxy-4-isopropenyl-3-pyrrolidineacetic acid; SR-01000075454; 2-Carboxy-3-carboxymethyl-4-isopropenylpyrrolidine; BRN 0086660; kainic-acid; (2S,3S,4S)-3-(carboxymethyl)-4-prop-1-en-2-ylpyrrolidine-2-carboxylic acid; NSC-759587; KAI; 1p1n; Kainic acid (synthetic); Biomol-NT_000217; UPCMLD-DP146; 3-Pyrrolidineacetic acid, 2-carboxy-4-(1-methylethenyl)-, (2S-(2alpha,3beta,4beta))-; Lopac0_000656; SCHEMBL15777; 4-22-00-01523 (Beilstein Handbook Reference); MLS001074661; BPBio1_001306; (-)-(.alpha.)-Kainic Acid; DTXSID7040526; UPCMLD-DP146:001; UPCMLD-DP146:002; HMS2233K05; HMS3262C13; HMS3266C11; HMS3411A21; HMS3675A21; HY-N2309; ZINC3995575; Tox21_110905; Tox21_500656; BDBM50002369; Kainic Acid - CAS 487-79-6; AKOS024456995; Tox21_110905_1; CCG-204742; LP00656; NSC-136038; SDCCGSBI-0050635.P002; NCGC00024504-02; NCGC00024504-03; NCGC00024504-04; NCGC00024504-06; NCGC00024504-07; NCGC00024504-08; NCGC00024504-09; NCGC00024504-15; NCGC00261341-01; R081; SMR000471885; B6226; CS-0020451; EU-0100656; K 0250; Q390239; SR-01000597728; SR-01000075454-1; SR-01000075454-5; SR-01000075454-6; SR-01000075454-7; SR-01000597728-1; rel-(3R,4R)-3-(carboxymethyl)-4-isopropenyl-D-proline; 2S-CARBOXY-4S-(1-METHYLETHENYL)-3S-PYRROLDINEACETIC ACID; L-proline, 3-(carboxymethyl)-4-(1-methylethenyl)-, (3S,4S)-; (2S,3S,4S)-3-(Carboxymethyl)-4-Prop-1-En-2-yl-Pyrrolidine-2-Carboxylicacid; 3-Pyrrolidineacetic acid, 2-carboxy-4-(1-methylethenyl)-, (2S-(2-alpha,3-beta,4-beta))- (9CI); 4071-38-9
• Drug Resistance Disease(s):
  Disease(s) with Clinically Reported Resistance for This Drug (1 diseases)
  Genetic epileptic syndromes [ICD-11: 8A61]; [1]
• Target: .; NOUNIPROTAC; [1]
• Formula: 4
• IsoSMILES: CC(=C)[C@H]1CN[C@@H]([C@H]1CC(=O)O)C(=O)O
• InChI: InChI=1S/C10H15NO4/c1-5(2)7-4-11-9(10(14)15)6(7)3-8(12)13/h6-7,9,11H,1,3-4H2,2H3,(H,12,13)(H,14,15)/t6-,7+,9-/m0/s1
• InChIKey: VLSMHEGGTFMBBZ-OOZYFLPDSA-N
• PubChem CID: 10255

Type(s) of Resistant Mechanism of This Drug

  EADR: Epigenetic Alteration of DNA, RNA or Protein

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-08: Nervous system diseases

Genetic epileptic syndromes [ICD-11: 8A61]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: Urothelial cancer associated 1 (UCA1) [1]

• Molecule Alteration: Up-regulation; Expression
• Resistant Disease: Temporal lobe epilepsy [ICD-11: 8A61.3Y]
• Experimental Note: Identified from the Human Clinical Data
• In Vivo Model: Epileptic rats model; Rattus norvegicus
• Experiment for Molecule Alteration: qRT-PCR; Immunofluorescence assay; Western bloting analysis; Overexpression assay
• Experiment for Drug Resistance: Morris water maze analysis
• Mechanism Description: LncRNA-UCA1 inhibits the astrocyte activation in the temporal lobe epilepsy via regulating the JAK/STAT signaling pathway.

References

• Ref 1: LncRNA-UCA1 inhibits the astrocyte activation in the temporal lobe epilepsy via regulating the JAK/STAT signaling pathwayJ Cell Biochem. 2020 Oct;121(10):4261-4270. doi: 10.1002/jcb.29634. Epub 2020 Jan 7.